Tempus AI, a leading technology company at the forefront of precision medicine, has announced the acquisition of Paige, a pioneer in artificial intelligence-driven digital pathology. This transformative deal, valued at $81.25 million and paid mainly in Tempus common stock, is set to accelerate Tempus’s mission of harnessing the power of AI in oncology while expanding its data and technical expertise. Additionally, Tempus will assume Paige’s commitments under its existing Microsoft Azure cloud services agreement.
Paige, founded in 2017, has demonstrated significant innovation in digital pathology, notably developing the first FDA-cleared AI application for pathology. This tool has empowered researchers and pathologists to detect cancer with greater accuracy, enabling healthcare professionals to make more informed and precise treatment decisions. Paige’s robust products are built upon a vast dataset comprising nearly seven million digitized pathology slide images, paired with clinical and molecular data—all carefully de-identified to protect patient privacy. The diversity of Paige’s dataset, which spans 45 countries and encompasses various genders, races, ethnicities, and regions, has contributed to the development of the first million-slide foundation model for cancer. This breakthrough enables researchers and life sciences companies to understand pathology data better and drive advancements in drug discovery and development.
By combining forces, Tempus and Paige are strategically positioned to build the largest foundation model ever constructed in oncology, radically transforming cancer diagnostics and treatment. The acquisition bolsters Tempus’s technical team with Paige’s deep experience in generative AI and further extends its reach into digital pathology. Ultimately, this partnership promises to catalyze progress across Tempus’s AI-driven initiatives, supporting physicians in delivering personalized, data-driven patient care and fostering the ongoing evolution of precision medicine.
KEY QUOTES:
“As we embark upon building the largest foundation model that’s ever been built in oncology, the acquisition of Paige substantially accelerates our efforts. Paige is a leader in digital pathology and has amassed one of the most comprehensive digital pathology datasets in the world through its relationship with Memorial Sloan Kettering Cancer Center. We believe both the Paige team, with their deep generative AI experience, and the dataset they have built, will be catalytic across all of our AI efforts.”
Eric Lefkofsky, Founder and CEO of Tempus
“We’ve always believed that the future of cancer care and precision medicine lies in harnessing the full potential of AI to redefine what’s possible in digital pathology and transform how cancer is detected, understood, and treated. By joining forces with Tempus, a company already making remarkable strides in oncology diagnostics, we can bring our innovations to a broader patient population and deliver even greater impact. We are confident this partnership is uniquely positioned to maximize and expand the reach of our technology, ensuring it fulfills our mission of delivering powerful, data-driven insights.”
Razik Yousfi, CEO and CTO of Paige
